Ribonucleotide reductase · PROTEIN COMPLEX · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Ribonucleotide reductase shows clinical signal disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P23921. Start with breast cancer, then reuse UniProt P23921 as the stable protein anchor across project notes and exports.
Start with breast cancer, then reuse UniProt P23921 as the stable protein anchor across project notes and exports.
Ribonucleotide reductase shows clinical signal disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with breast cancer because it currently carries clinical signal support. Linked drugs include TRIAPINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyRibonucleoside-diphosphate reductase large subunit
Review this target as Ribonucleotide reductase, mapped to UniProt P23921. ChEMBL maps the protein component as Ribonucleoside-diphosphate reductase large subunit. Sequence length is 792 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Ribonucleotide reductase as ChEMBL target CHEMBL3301398, mapped to UniProt P23921. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Ribonucleotide reductase is the right protein anchor across sources, using UniProt P23921 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why breast cancer is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Ribonucleotide reductase |
| Target Type | PROTEIN COMPLEX |
| Organism | Homo sapiens |
| UniProt | P23921 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Ribonucleoside-diphosphate reductase large subunit |
| UniProt Accession | P23921 |
| Component Type | Protein |
| Sequence Length | 792 aa |
Ribonucleoside-diphosphate reductase large subunit
Review this target as Ribonucleotide reductase, mapped to UniProt P23921. ChEMBL maps the protein component as Ribonucleoside-diphosphate reductase large subunit. Sequence length is 792 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Ribonucleotide reductase shows clinical signal disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block.
Start review with breast cancer because it currently carries clinical signal support. Linked drugs include TRIAPINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL6001460 | 7.7 | IC50 | 20.0 | Preclinical |
| CHEMBL5913113 | 7.52 | IC50 | 30.0 | Preclinical |
| CHEMBL5941178 | 7.52 | IC50 | 30.0 | Preclinical |
| CHEMBL5777432 | 7.4 | IC50 | 40.0 | Preclinical |
| CHEMBL5958580 | 7.4 | IC50 | 40.0 | Preclinical |
| CHEMBL5797621 | 7.3 | IC50 | 50.0 | Preclinical |
| CHEMBL5813221 | 7.3 | IC50 | 50.0 | Preclinical |
| CHEMBL5987707 | 7.3 | IC50 | 50.0 | Preclinical |
| CHEMBL6028518 | 7.3 | IC50 | 50.0 | Preclinical |
| CHEMBL5775741 | 7.22 | IC50 | 60.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| protein complex format | 9 | 6 | 5.1 |
| cell-based format | 3 | 0 | — |
| assay format | 1 | 260 | 6.7 |